Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and […]
SINGAPORE and BURLINGTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) — Helport AI Limited (together with its operating subsidiaries, “Helport”) (Nasdaq: […]
BETHESDA, Md., Aug. 02, 2024 (GLOBE NEWSWIRE) — iLearningEngines, Inc. (NASDAQ: AILE) (“iLearningEngines” or “ILE”) a leader in AI-powered learning […]